

The SCC-AFTER research study aims to find out whether it is better to use radiotherapy or not to prevent high-risk skin cancer from coming back after it has been removed by surgery

Submission date 04/06/2024	Recruitment status Recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 02/07/2024	Overall study status Ongoing	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 18/02/2026	Condition category Cancer	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Some squamous cell cancers are called 'high-risk', meaning that there is a higher chance that they could come back after surgery compared to other skin cancers. Around 3 out of 10 people with high-risk skin cancer may experience their cancer coming back within 3 years of the surgery. Radiotherapy (x-ray treatment) is sometimes given to people with high-risk skin cancer after surgery to try and reduce the chances of the cancer coming back. This is called 'post-operative' or 'adjuvant radiotherapy'. It is given to the area of the skin where the cancer was removed. It works by using X-rays to destroy any cancer cells that might be left behind in that area. However, there is no certainty that radiotherapy does stop high-risk skin cancers from coming back. The alternative to radiotherapy is to start a close clinical follow-up to monitor if the skin cancer shows signs of coming back and to treat it if it does. This study aims to find out whether using radiotherapy in people who have had high-risk squamous cell cancer removed by surgery reduces the chances of their skin cancer coming back, or whether radiotherapy is not necessary and only close clinical follow-up is required. The study will also find out what impact it has on quality of life.

Who can participate?

People aged 18 years old and over who have had this type of high-risk skin cancer removed with surgery

What does the study involve?

The study will have two groups of patients:

Radiotherapy and close clinical follow-up:

- Will receive treatment with radiotherapy every weekday for 2-6 weeks, starting within 4 months of the surgery that removed the cancer.
- Will be followed up closely for 3 years to see if the skin cancer shows signs of returning.
- Will be unlikely to have radiotherapy again in the future if the skin cancer does return to the same place.

Close clinical follow-up:

- Will be followed up closely for 3 years to see if the skin cancer shows signs of returning.
- May be able to have radiotherapy in the future if the skin cancer does return to the same place.

There is a linked study that wants to find out more about how patients feel about taking part in the trial. It will involve somebody asking patients questions about their experience and these will be recorded.

What are the possible benefits and risks of participating?

Possible benefits of Radiotherapy followed by close clinical follow-up:

- Radiotherapy may lower the risk of a patient's cancer coming back.

Possible benefits of Close clinical follow-up:

- Patients will not need to attend for daily radiotherapy or experience the side effects that may come with radiotherapy.
- Radiotherapy has not been proven to lower the risk of a patient's cancer coming back.
- Patients may be able to have radiotherapy at a later date if their cancer does come back.

Possible risks of Radiotherapy followed by close clinical follow-up:

- Radiotherapy has not been proven to lower the risk of a patient's cancer coming back.
- Patients would not be able to have further radiotherapy in the same area if the cancer comes back in the same place and would therefore need different treatment.
- Radiotherapy is generally very well tolerated, however, there are possible short-term and long-term side effects from radiotherapy:

Short term: Skin redness, irritation, itching, flaking, peeling, scaling and dryness in the treatment area. The skin may scab over or break down in the treatment area. General tiredness during the treatment period. Some side effects can be specific, such as potential interactions with other medicines a patient may take or with a pacemaker. This may affect the radiotherapy. These will be discussed with the medical team.

Long-term: Permanent skin texture changes in the treatment area are possible and include thicker or thinner skin, skin colour change and rarely a more long-term non-healing ulcer that may require further treatment such as dressings or surgery. If radiotherapy is given to an area on the body where hair grows such as the scalp, it can sometimes cause permanent hair loss.

Possible risks of Close clinical follow-up:

- The cancer may come back even though a patient has had surgery and may require further treatment, such as surgery or radiotherapy.

Where is the study run from?

The study is being co-ordinated by the Centre for Trials Research on behalf of Cardiff University.

When is the study starting and how long is it expected to run for?

January 2024 to January 2031

Who is funding the study?

National Institute for Health and Care Research (NIHR)

Who is the main contact?

SCCAFTER@cardiff.ac.uk

Contact information

Type(s)

Public, Scientific

Contact name

Ms Ann White

ORCID ID

<https://orcid.org/0000-0001-7317-6304>

Contact details

Centre for Trials Research (CTR) – Cancer Group
College of Biomedical & Life Sciences
Cardiff University
6th Floor, Neuadd Meirionnydd
Heath Park
Cardiff
United Kingdom
CF14 4YS
+44 (0)2920687465
SCCAFTER@cardiff.ac.uk

Type(s)

Principal investigator

Contact name

Prof Catherine Harwood

ORCID ID

<https://orcid.org/0000-0002-1375-0965>

Contact details

The Royal London Hospital
Barts Health NHS Trust
London
United Kingdom
E1 1BB
+44 (0)20 7882 2332
SCCAFTER@cardiff.ac.uk

Type(s)

Principal investigator

Contact name

Prof Agata Rembielak

ORCID ID

<https://orcid.org/0000-0003-2351-7179>

Contact details

The Christie NHS Foundation Trust
Wilmslow Road
Manchester
United Kingdom
M20 4BX
+44 (0)161 446 8583
SCCAFTER@cardiff.ac.uk

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Integrated Research Application System (IRAS)

331136

Protocol serial number

SPON1924-22

Central Portfolio Management System (CPMS)

62841

Study information

Scientific Title

Adjuvant radiotherapy in patients with high-risk primary cutaneous Squamous Cell Carcinoma AFTER surgery (SCC-AFTER): an open-label, multicentre, two-arm phase III randomised trial

Acronym

SCC-AFTER

Study objectives

Following complete excision of high-risk primary cutaneous squamous cell carcinoma (HR cSCC) is adjuvant radiotherapy (ART) plus standard clinical follow up superior in reducing loco-regional recurrence compared with standard clinical follow up alone?

Ethics approval required

Ethics approval required

Ethics approval(s)

approved 11/04/2024, East of England - Essex Research Ethics Committee (2 Redman Place, London, EC20 1JQ, United Kingdom; +44 (0)207 104 8106; Essex.REC@hra.nhs.uk), ref: 24/EE/0049

Study design

Multicentre interventional open-label two-arm Phase III randomized controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Adjuvant radiotherapy in patients with high-risk primary cutaneous Squamous Cell Carcinoma (a non-melanoma skin cancer) after surgery

Interventions

This study aims to find out whether using radiotherapy in people who have had high-risk skin cancer removed by surgery reduces the chances of their skin cancer coming back, or whether radiotherapy is not necessary and only close clinical follow-up is required. This is an open-label, multicentre, two-arm, phase III randomised control trial to evaluate superiority, cost-effectiveness, and effects on quality of life (QoL) of adjuvant radiotherapy (ART) in completely resected high-risk (BWH T2b/3) primary cutaneous squamous cell carcinoma (cSCC).

Patients will be randomised to either the ART followed by close clinical follow-up (ART arm) or close clinical follow-up only (comparator arm and current standard care). Patients will be assessed following UK guidance at baseline, mid-ART (ART arm only), 4 monthly for 2 years, then 6-monthly for year 3. During the follow-up period, QoL and Health Economics (HE) will be assessed twice for year 1, and annually in years 2 and 3. Progression and survival data will be collected throughout the trial.

Participants will be randomised using unweighted minimisation with a 20% random element. The stratification/balancing variables are detailed below.

STRATIFICATION/BALANCING VARIABLES

The balancing factors will be:

- Age
 - o Less than 65
 - o ≥ 65 to < 80
 - o 80 or over
- Stage of cancer BWH classification
 - o T2b
 - o T3
- Immunocompromised
 - o Yes
 - o No
- Time since surgery (months)
 - o $<$ Three months
 - o Three to \leq four months
- Perineural invasion (nerve diameter ≥ 0.1 mm)
 - o Yes
 - o No

Each factor will have equal weighting.

An internal pilot targeting the recruitment of 100 patients within the first 12 months will determine feasibility. Two interim analyses after 77 and 115 events (600-760 randomised) trigger early stopping if the log-rank statistic is larger than ± 3.36 and ± 2.68 respectively. Stopping for efficacy means fewer participants and shorter follow-ups. Otherwise, the trial will be analysed when at least 194 events have been reported.

A Quintet Recruitment Intervention (QRI) and INCLUSION Study Within a Project (SWAP) are integrated within the trial to optimise recruitment and inclusion of people with multiple long-term conditions, safeguard informed consent, address clinician equipoise, and identify organisational barriers.

Intervention Type

Procedure/Surgery

Primary outcome(s)

Loco-regional recurrence (LRR)-free survival time, time to LRR is defined as the time from randomisation to date of clinical detection of what is subsequently confirmed to be local, regional, or loco-regional recurrent disease, measured using physical examination at a skin clinic at 4, 8, 16, 12, 24, and 36 months following randomisation until the end of the study

Key secondary outcome(s)

1. Quality of life (QOL) measured using EORTC QLQ C30, skin-specific Skin Cancer Index, Picker Patient Experience 15 questionnaire and EQ-5D at 4, 12, 24, and 36 months post-randomisation
2. Distant metastasis-free survival, defined as days from randomisation to the date of distant metastasis or death from any cause, measured using data reported by completion of recurrence CRF from randomisation until the point of recurrence is confirmed or death
3. Overall survival, defined as days from randomisation to death for any reason, measured using data reported by completion of a death CRF at the date of death
4. Safety/toxicity as assessed by common terminology criteria for adverse events (CTCAE) V5.0 scoring system and serious adverse events, including patient-reported outcomes version of the CTCAE, measured using adverse event CRFs at 4, 8, 16, 24, 26 months post-randomisation
5. Cost-effectiveness measured using health utility using EQ-5D-5L and recording health resource use at 4, 12, 24, and 36 months post-randomisation. The primary economic outcome is cost per quality-adjusted life year (QALY). The secondary economic outcome is resource use and costs.

Completion date

01/01/2031

Eligibility

Key inclusion criteria

Current inclusion criteria as of 18/02/2026:

1. High-risk primary cSCC (T2b/T3 by BWH staging criteria) excised with histologically clear peripheral and deep margins (≥ 1 mm by RCPATH criteria*). Surgical excision margins should be consistent with BAD guidelines (peripheral and deep) and will be recorded.
2. Time since excision surgery < 3 months (< 4 months acceptable only if necessary)
3. ECOG performance status of 0, 1, 2, or 3 at enrolment (Appendix 1)
4. Aged 18 years or older at time of consent
5. Fit for ART and able to attend radiotherapy outpatient appointments
6. Life expectancy >6 months
7. Informed Consent obtained** which must be prior to any mandatory study-specific procedures, sampling, and analyses

*For SCC on the scalp, a deep histological margin of 0.8 mm - <1 mm is eligible if the deep margin of excision was confirmed to have resected either galea or galea and periosteum or galea,

periosteum and bone; the galea is not infiltrated by tumour; the peripheral histological margins are 1mm or greater; the SSMDT assesses that surgical treatment is complete

Previous inclusion criteria:

1. High-risk primary cSCC (T2b/T3 by BWH staging criteria) excised with adequate peripheral and deep surgical margins (according to BAD guidelines) with histologically clear margins (≥ 1 mm by Royal College of Pathology criteria)
2. Time since excision surgery < 3 months (<2 months is preferred)
3. ECOG performance status of 3 or less at enrolment
4. Aged 18 years or older at time of consent
5. Fit for ART and able to attend radiotherapy outpatient appointments
6. Life expectancy >6 months
7. Informed Consent obtained* which must be prior to any mandatory study-specific procedures, sampling, and analyses

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Mixed

Lower age limit

18 years

Upper age limit

100 years

Sex

All

Total final enrolment

0

Key exclusion criteria

1. Any current clinicopathological evidence of loco-regional recurrence of the index tumour
2. Previous (within 3 years) or current non-index primary cSCC in skin drained by the same lymph node basin
3. cSCC on anatomical sites which interfere with suitability for ART (such as vermilion lip, eyelids, breast, anogenital area)
4. Patients with evidence of regional or distant disease at time of primary cSCC diagnosis
5. Previous radiotherapy in the same area
6. Patients with reproductive potential who are not willing to use contraception for the duration from trial consent until the last dose of radiotherapy if they are randomised to the ART arm
7. Unable to lie still unattended for the duration of ART (estimated to be around 5 minutes)
8. Participation in another interventional clinical study that may affect the recurrence of cSCC (primary endpoint)

9. History of another malignancy where metastasis could cause diagnostic uncertainty or patients receiving active systemic anti-cancer treatment (excluding hormonal treatment for prostate or breast cancer) or radiotherapy

Date of first enrolment

31/07/2024

Date of final enrolment

14/06/2027

Locations

Countries of recruitment

United Kingdom

England

Northern Ireland

Scotland

Wales

Study participating centre

The Christie

550 Wilmslow Road

Withington

Manchester

England

M20 4BX

Study participating centre

Kings Mill Hospital

Sherwood Forest NHS Trust

Mansfield Rd

Sutton-in-Ashfield

England

NG17 4JL

Study participating centre

Velindre Cancer Centre

Velindre Road

Cardiff

Wales

CF14 2TL

Study participating centre
Nottingham University Hospitals NHS Trust - City Campus
Nottingham City Hospital
Hucknall Road
Nottingham
England
NG5 1PB

Study participating centre
Sheffield Teaching Hospitals NHS Foundation Trust
Northern General Hospital
Herries Road
Sheffield
England
S5 7AU

Study participating centre
Tayside
Ninewells Hospital
Dundee
Scotland
DD1 9SY

Study participating centre
Cambridge University Hospitals NHS Foundation Trust
Cambridge Biomedical Campus
Hills Road
Cambridge
England
CB2 0QQ

Study participating centre
Clatterbridge Cancer Centre
Clatterbridge Hospital
Clatterbridge Road
Wirral
England
CH63 4JY

Study participating centre
James Cook University Hospital
Marton Road
Middlesbrough
England
TS4 3BW

Study participating centre
Barking, Havering and Redbridge University Hospitals NHS Trust
Queens Hospital
Rom Valley Way
Romford
England
RM7 0AG

Study participating centre
East Lancashire Hospitals NHS Trust
Royal Blackburn Hospital
Haslingden Road
Blackburn
England
BB2 3HH

Study participating centre
Maidstone & Tunbridge Wells NHS Trust Hq
Maidstone Hospital
Hermitage Lane
Maidstone
England
ME16 9QQ

Study participating centre
Churchill Hospital
Churchill Hospital
Old Road
Headington
Oxford
England
OX3 7LE

Study participating centre

Barts and the London NHS Trust

Alexandra House
The Royal London Hospital
Whitechapel
London
England
E1 1BB

Study participating centre

Singleton Hospital

Sketty Lane
Sketty
Swansea
Wales
SA2 8QA

Study participating centre

Mount Vernon Cancer Centre

Rickmansworth Road
Northwood
England
HA6 2RN

Study participating centre

Norfolk and Norwich University Hospitals NHS Foundation Trust

Colney Lane
Colney
Norwich
England
NR4 7UY

Study participating centre

Northampton General Hospital

Cliftonville
Northampton
England
NN1 5BD

Study participating centre

Queen Elizabeth Hospital

Queen Elizabeth Medical Centre

Edgbaston
Birmingham
England
B15 2TH

Study participating centre
Royal Surrey NHS Foundation Trust
Egerton Road
Guildford
England
GU2 7XX

Study participating centre
Derriford Hospital
Derriford Road
Derriford
Plymouth
England
PL6 8DH

Study participating centre
University Hospitals Dorset NHS Foundation Trust
Management Offices
Poole Hospital
Longfleet Road
Poole
England
BH15 2JB

Study participating centre
Musgrove Park Hospital
Musgrove Park
Taunton
England
TA1 5DA

Study participating centre
Beatson West of Scotland Cancer Centre
1053 Great Western Road

Glasgow
Scotland
G12 0YN

Study participating centre
Glan Clywd Hospital
Rhuddlan Rd, Bodelwyddan
Rhyl
Wales
LL18 5UJ

Study participating centre
Belfast City -Northern Ireland Cancer Centre
10 Jubilee Road
Belfast
Northern Ireland
BT9 7JL

Sponsor information

Organisation
Cardiff University

ROR
<https://ror.org/03kk7td41>

Funder(s)

Funder type
Government

Funder Name
National Institute for Health and Care Research

Alternative Name(s)
National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type
Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan

The final datasets generated and analysed during the trial will be available upon request directly from the sponsor subject to review using SCCAFTER@cardiff.ac.uk.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol file	version 1.1	18/03/2024	01/07/2024	No	No
Protocol file		09/12/2025	18/02/2026	No	No
Study website		11/11/2025	11/11/2025	No	Yes